Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers

NCT ID: NCT02102464

Last Updated: 2017-10-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The pilot study objective is to evaluate the potential benefits of LipiFlow® System treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye by assessing for improvement in meibomian gland function and reduction of dry eye symptoms in comparison to an untreated control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, non-significant risk, open-label, randomized clinical trial of LipiFlow® treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye. All subjects undergo examination to determine study eligibility and to capture the Baseline status. Subjects are randomized to receive LipiFlow® treatment (Treatment Group) or no LipiFlow® treatment (Untreated Control Group). The Treatment group is evaluated one month after receiving LipiFlow® treatment. Study endpoints are evaluated at 3 Months by comparing the Treatment Group to the Untreated Group. To facilitate subject recruitment, the Untreated Control group receives Crossover LipiFlow® treatment (Crossover Treatment Group) at 3 Months. The Crossover Treatment group is evaluated one month after receiving LipiFlow® treatment (4 Months visit).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meibomian Gland Dysfunction Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LipiFlow

Single 12-minute LipiFlow treatment

Group Type EXPERIMENTAL

LipiFlow treatment

Intervention Type DEVICE

The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.

Untreated Control

Untreated Control (No Intervention)

Group Type NO_INTERVENTION

No interventions assigned to this group

Crossover LipiFlow Treatment

Crossover LipiFlow treatment of the untreated control group after 3 months

Group Type EXPERIMENTAL

LipiFlow treatment

Intervention Type DEVICE

The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LipiFlow treatment

The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LipiFlow® Thermal Pulsation System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of meibomian gland dysfunction and dry eye
* At least 18 years of age
* Willing to comply with randomization, attend all study visits and follow patient instructions
* Habitual soft contact lens wearer 2 to 18 hours/day and 4 to 7 days/week
* No change in contact lens type or dimensions for the past 3 months
* Clinician assessment of acceptable contact lens fit and disinfecting solution
* Tear film interferometry of 100 units or less

Exclusion Criteria

* Systemic disease conditions that cause dry eye
* Use of systemic medications known to cause dryness
* History of any of the following ocular conditions in the past 3 months: surgery, trauma, Herpes infection, recurrent inflammation, punctal plug insertion or punctal occlusion
* Presence of any of the following active conditions: ocular infection, ocular inflammation, moderate to severe allergic conjunctivitis, severe eyelid inflammation, eyelid abnormality that affects lid function, or ocular surface abnormality that compromises corneal integrity
* Use of other treatments for meibomian gland dysfunction or dry eye except over the counter lubricants or dietary supplements
* Participation in another ophthalmic drug or device trial in the past month
* Employee, relative of employee or associate of the clinical site
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TearScience, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christy Coleman, OD, MPH

Role: STUDY_DIRECTOR

TearScience, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

School of Optometry, The University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Clayton Eye Center

Morrow, Georgia, United States

Site Status

Charlotte Eye Ear Nose and Throat Associates, P.A.

Charlotte, North Carolina, United States

Site Status

May Eye Care Center & Associates

Hanover, Pennsylvania, United States

Site Status

Specialty Eyecare Group

Kirkland, Washington, United States

Site Status

Centre for Contact Lens Research

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LF006

Identifier Type: -

Identifier Source: org_study_id